KXV01 TCR Lentinvivo Injection

DRUG4 trials

Sponsors

TCRx Therapeutics Co.Ltd, The First Hospital of Jilin University, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions

Advanced Solid CancerAdvanced Solid TumorsMetastatic Solid TumorsRare Malignant Neoplasm

Phase 1

Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors

Not yet recruitingNCT07196579

TCRx Therapeutics Co.LtdAdvanced Solid Cancer

Start: 2025-10-01End: 2028-12-31Target: 30Updated: 2025-09-29

Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors

Not yet recruitingNCT07207681

The First Hospital of Jilin UniversityAdvanced Solid Tumors

Start: 2025-10-15End: 2028-12-31Target: 30Updated: 2025-10-06

Personalized KXV01 Lentinvivo (TCR) Injection as the Therapy for Advanced Solid Tumors

Not yet recruitingNCT07275853

TCRx Therapeutics Co.LtdAdvanced Solid Tumors

Start: 2025-12-01End: 2028-12-31Target: 30Updated: 2025-12-10

Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)

Not yet recruitingNCT07307053

Cancer Institute and Hospital, Chinese Academy of Medical SciencesAdvanced Solid Tumors, Metastatic Solid Tumors, Rare Malignant Neoplasm

Start: 2026-01-01End: 2031-01-31Target: 600Updated: 2025-12-29